With shares of CVS Caremark (NYSE:CVS) trading around $57, is CVS an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:
T = Trends for a Stock’s Movement
CVS Caremark�is a pharmacy healthcare provider in the United States.�The company operates in three business segments: Pharmacy Services, Retail Pharmacy, and Corporate. The products and services offered at CVS Caremark stores may be deemed as essential by many consumers in the United States. As CVS Caremark provides an efficient and affordable healthcare and pharmacy experience, look for it to see rising profits. The healthcare sector is seeing a massive change that may benefit companies like this one for many years.
T = Technicals on the Stock Chart are Strong
CVS Caremark stock has witnessed a powerful move over the last several years. The stock is now consolidating near all-time high prices and might get going after it digests recent gains. Analyzing the price trend and its strength can be done using key simple moving averages. What are the key moving averages? The 50-day (pink), 100-day (blue), and 200-day (yellow) simple moving averages. As seen in the daily price chart below, CVS Caremark is trading near its rising key averages which signal neutral to bullish price action in the near-term.
Top Telecom Companies For 2015: Pharmacyclics Inc (PCYC)
Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.
As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.
Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).
PCI-27483 Factor VIIa Inhibitor
The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.
Factor VIIa PCI-27483 Clinical Development Update
A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.
A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.Advisors' Opinion:
- [By Maxx Chatsko]
The astounding rise of Pharmacyclics (NASDAQ: PCYC ) through the markets has been largely based on its BTK inhibitor ibrutinib, which is being evaluated in four types of blood cancers and in a preclinical study for autoimmune indications. The rise is no fluke, either. Ibrutinib has shown very promising results in two phase 2 trials as a monotherapy and will soon be moved to phase 3 trials for both. With billions of dollars between the lymphoma and autoimmune markets up for grabs, it is easy to see why shares have risen 2,000% since the company acquired its lead drug candidate in 2006. Can Celgene tap into this multibillion opportunity with CC-292? Ask me again in about five years.�
5 Best Tech Stocks To Own Right Now: Malaysian Pacific Industries Bhd (MPI)Malaysian Pacific Industries Berhad (MPI) is an investment holding company. The principal activities of MPI, through its subsidiaries are manufacturing, assembling, testing and sale of integrated circuits, semiconductor devices, electronic components and lead frames to customers globally. The Company�� operating geographical segments include Asia, The United States of America, and Europe. The Company's subsidiaries include Carsem (M) Sdn Bhd, Recams Sdn Bhd, Carsem Holdings Limited, Carsem Semiconductor (Suzhou) Co., Ltd, Dynacraft Industries Sdn Bhd, Carter Realty Sdn Bhd, Carter Realty Sdn Bhd and Carsem Holdings (HK) Limited. Advisors' Opinion:
- [By Sofia Horta e Costa]
Michael Page International Plc (MPI) increased 1.1 percent to 490.2 pence after Goldman Sachs Group Inc. upgraded the stock to buy from neutral, saying the recruitment firm will benefit from a pick-up in the European economy.
5 Best Tech Stocks To Own Right Now: Medical Cannabis Payment Solutions (REFG.PK)
Medical Cannabis Payment Solutions, incorporated on December 1, 2005, is a provider of integrated supply and distribution technology. The Company�� Seed-to-Sale (S2S) integrated solution is a management and compliance technology for growers, caregivers and dispensaries in the market. The Company also works with public officials and government agencies to expand the acceptance of medicinal cannabis, and the adoption of a legal framework where maximum market expansion is possible. The Company solves the fragmentation problem by identifying tools that are important to dispensaries, and customizing those tools specifically catered to the industry. The Company's solutions include Spark, Ghost and S2S.
The Company�� SPARK Hosted Voice over Internet Protocol (VoIP) provides customers with enterprise-class hosted phone systems customized to fit customers��needs. SPARK's service is a fully-managed, cloud-based system. The Company offers the convenience of an online Internet Protocol (IP)-based telecommunications system while still delivering substantial savings to customers bottom line.
By offering customers a customized, tailored mobile solution, the Company's Ghost Mobile Apps give a marketing tool with a texting and e-mail solution, keeping customers in constant contact with patients and clients. The Company creates an optimized experience in context to each device or screen size.Advisors' Opinion:
- [By Alan Brochstein]
Not too surprisingly, supply is starting to increase. We have seen some companies enter the space by expanding their own businesses, but there have been some reverse mergers lately too. I had mentioned Refill Energy (REFG.PK) recently (soon to be Medical Cannabis Financial Group), but earlier this month Promap (PMAP.OB) acquired 94% of Advanced Cannabis Solutions (link to 8-K). As an aside, I think that this company is worth considering given the management team and the business model. Investors should keep in the back of their mind that there are many companies that are quietly developing their business models and could become public over time, especially as the regulatory and legal landscapes improve.
5 Best Tech Stocks To Own Right Now: Vimicro International Corporation(VIMC)
Vimicro International Corporation, through its subsidiaries, designs, develops, and markets mixed-signal semiconductor products and system-level solutions for the consumer electronics, communications, and surveillance markets in Mainland China, Taiwan, Japan, Korea, and Hong Kong. It provides mixed-signal multimedia processors for personal computer and embedded notebook cameras, as well as for mobile phones. The company also offers system-level solutions that include integrated semiconductors, customizable firmware and software, software development tools, reference designs, and applications support. In addition, it provides security and surveillance products comprising video capturing, compression, transmission, storage, processing, display, and video analysis products. Further, the company involves in packaging, testing, and reselling third party image sensors. It sells its multimedia processor products through direct sales force and distributors to original design manuf acturers, original equipment manufacturers, design houses, and module manufacturers, as well as its security and surveillance products to government entities, telecommunications operators, schools, banks, railway companies, supermarkets, and theaters. The company was founded in 1999 and is based in Beijing, the People?s Republic of China.Advisors' Opinion:
- [By John Udovich]
Small cap security and surveillance stocks like Vimicro International Corporation (NASDAQ: VIMC), TASER International, Inc (NASDAQ: TASR), Kratos Defense & Security Solutions, Inc (NASDAQ: KTOS)�and View Systems Inc (OTCBB: VSYM) have been producing a steady stream of news lately for investors and traders alike to digest. After all, the entire�security and surveillance industry is pretty vast as it would include everything from airport scanners to security cameras or monitoring equipment to actual weapons for domestic or national defense to software securing everyone�� personal or online data to the technology groups like the NSA and other "Big Brother" agencies use to spy on us. With that in mind, here is a look at the latest news from important small cap security and surveillance stocks:
- [By Paul Ausick]
Beijing-based Vimicro International Corp. (NASDAQ: VIMC) was up about 33% after the company raised its guidance for the fourth quarter of 2013 and the first quarter of 2014. The company is a fabless designer and marketer of mixed-signal processors and other products for the consumer, communications and surveillance markets in China and Hong Kong. Shares trade at around $4.00 in a 52-week range of $1.10 to $4.64, and that high was set earlier today. About 1.4 million shares had traded hands, more than 10 times the daily average of around 100,000.
- [By John Udovich]
Small cap security and surveillance stocks OSI Systems, Inc (NASDAQ: OSIS), Vimicro International Corporation (NASDAQ: VIMC), Analogic Corporation (NASDAQ: ALOG), Lifelock Inc (NYSE: LOCK) and View Systems Inc (OTCBB: VSYM) have been producing a steady flow of news lately that investors might want to take a closer look at. After all, the whole security and surveillance industry is pretty vast as it would include everything from airport scanners to security cameras to software securing everyone�� personal or online data. With that in mind, here is a look at the latest news from important small cap security and surveillance stocks:
- [By John Udovich]
Small cap stocks Vimicro International Corporation (NASDAQ: VIMC), Cohu, Inc (NASDAQ: COHU) and View Systems Inc (OTCBB: VSYM) are also surveillance and security stocks because they�also offer products that can be used to keep an eye on us���for better or for worst. After all and go to any public space (whether its a shopping mall, entertainment venue or even a street corner), you will probably see (or maybe not see) some sort of security or surveillance equipment. With that in mind, here is a look at three small cap surveillance and security stocks you may have overlooked: